Published by Josh White on 28th October 2022
(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.
URL: http://www.digitallook.com/dl/news/story/33069661/...